AI assistant
MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED — Director's Dealing 2016
Apr 10, 2016
65387_rns_2016-04-10_06daaf73-ed08-48d6-9bd7-205397b67c9e.pdf
Director's Dealing
Open in viewerOpens in your device viewer
Appendix 3Y Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity Medical Developments International Limited ABN 14 106 340 667
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of Director | David Williams |
|---|---|
| Date of last notice | 1 March 2016 |
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Direct or indirect interest | Lawn Views Pty Ltd – Indirect Moggs Creek Pty Ltd – Indirect Mr. David Williams (Trustee) - Indirect Kidder Peabody Pty Ltd – Indirect Ward Williams – Indirect Saul Williams – Indirect |
|---|---|
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. |
Lawn Views Pty Ltd – 7,834,119 Moggs Creek Pty Ltd – 8,043,912 Mr. David Williams (Trustee) – 822,000 Kidder Peabody Pty Ltd – 1,000,000 Ward Williams – 23,446 Saul Williams – 8,513 |
| Date of change | 8 April 2016 |
| No. of securities held prior to change | 17,731,990 |
| Class | Fully Paid Ordinary Shares |
| Number acquired | 77,865 |
| Number disposed | Nil |
- See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Appendix 3Y Change of Director’s Interest Notice
Value/Consideration 77,865 shares @ $4.56 via participation in
Note: If consideration is non-cash, provide details and estimated valuation the Dividend Reinvestment Plan
No. of securities held after change 17,809,855 Nature of change Issue of shares via participation in the
Example: on-market trade, off-market trade, exercise of options, MVP Dividend Reinvestment Plan issue of securities under dividend reinvestment plan, participation in
buy-back announced on 18 February 2016.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
==> picture [434 x 319] intentionally omitted <==
----- Start of picture text -----
Detail of contract Not applicable
Nature of interest
Name of registered holder
(if issued securities)
Date of change
No. and class of securities to which
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details
and an estimated valuation
Interest after change
----- End of picture text -----
Part 3 –[+] Closed period
Were the interests in the securities or contracts detailed above No traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to N/A proceed during this period? If prior written clearance was provided, on what date was this N/A provided?
- See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Appendix 3Y Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity Medical Developments International Limited ABN 14 106 340 667
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director Mr. Robert Maxwell Johnston
Date of last notice 31 October 2013
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Direct or indirect interest | Indirect |
|---|---|
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. |
JONDOL PTY LTD – Superannuation Fund |
| Date of change | 8 April 2016 |
| No. of securities held prior to change | 30,000 |
| Class | Fully Paid Ordinary Shares |
| Number acquired | 131 |
| Number disposed | Nil |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation |
131 shares @ $4.56 via participation in the Dividend Reinvestment Plan |
| No. of securities held after change | 30,131 |
- See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Appendix 3Y Change of Director’s Interest Notice
Nature of change Issue of shares via participation in the Example: on-market trade, off-market trade, exercise of options, MVP Dividend Reinvestment Plan issue of securities under dividend reinvestment plan, participation in buy-back announced on 18 February 2016.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
==> picture [434 x 319] intentionally omitted <==
----- Start of picture text -----
Detail of contract Not applicable
Nature of interest
Name of registered holder
(if issued securities)
Date of change
No. and class of securities to which
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details
and an estimated valuation
Interest after change
----- End of picture text -----
Part 3 –[+] Closed period
Were the interests in the securities or contracts detailed No above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade N/A to proceed during this period? If prior written clearance was provided, on what date was this N/A provided?
- See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Appendix 3Y Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity Medical Developments International Limited ABN 14 106 340 667
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of Director | Allan McCallum |
|---|---|
| Date of last notice | 30 September 2015 |
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Direct or indirect interest | Indirect |
|---|---|
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. |
Mullacam Pty Ltd – 329,235 McCallum Family Super fund – 50,787 |
| Date of change | 8 April 2016 |
| No. of securities held prior to change | 380,022 |
| Class | Fully Paid Ordinary Shares |
| Number acquired | 1,668 |
| Number disposed | Nil |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation |
1,668 shares @ $4.56 via participation in the Dividend Reinvestment Plan |
| No. of securities held after change | 381,690 |
- See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Appendix 3Y Change of Director’s Interest Notice
Nature of change Issue of shares via participation in the Example: on-market trade, off-market trade, exercise of options, MVP Dividend Reinvestment Plan issue of securities under dividend reinvestment plan, participation in buy-back announced on 18 February 2016.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
==> picture [434 x 319] intentionally omitted <==
----- Start of picture text -----
Detail of contract Not applicable
Nature of interest
Name of registered holder
(if issued securities)
Date of change
No. and class of securities to which
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details
and an estimated valuation
Interest after change
----- End of picture text -----
Part 3 –[+] Closed period
Were the interests in the securities or contracts detailed No above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade N/A to proceed during this period? If prior written clearance was provided, on what date was this N/A provided?
- See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Appendix 3Y Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity Medical Developments International Limited ABN 14 106 340 667
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director Harry Oxer
Date of last notice 11 October 2013
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Direct or indirect interest | Direct |
|---|---|
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. |
Dr. Harry Frank Oxer |
| Date of change | 8 April 2016 |
| No. of securities held prior to change | 207,013 |
| Class | Fully Paid Ordinary Shares |
| Number acquired | 909 |
| Number disposed | Nil |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation |
909 shares @ $4.56 via participation in the Dividend Reinvestment Plan |
| No. of securities held after change | 207,922 |
- See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Appendix 3Y Change of Director’s Interest Notice
Nature of change Issue of shares via participation in the Example: on-market trade, off-market trade, exercise of options, MVP Dividend Reinvestment Plan issue of securities under dividend reinvestment plan, participation in buy-back announced on 18 February 2016.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
==> picture [434 x 319] intentionally omitted <==
----- Start of picture text -----
Detail of contract Not applicable
Nature of interest
Name of registered holder
(if issued securities)
Date of change
No. and class of securities to which
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details
and an estimated valuation
Interest after change
----- End of picture text -----
Part 3 –[+] Closed period
Were the interests in the securities or contracts detailed No above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade N/A to proceed during this period? If prior written clearance was provided, on what date was this N/A provided?
- See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Appendix 3Y Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity Medical Developments International Limited ABN 14 106 340 667
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director Mr. Philip Powell
Date of last notice 30 September 2015
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Direct or indirect interest | Indirect |
|---|---|
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. |
PNSF Pty Ltd as trustee for the Prime Numbers Superannuation Fund |
| Date of change | 8 April 2016 |
| No. of securities held prior to change | 252,074 |
| Class | Fully Paid Ordinary Shares |
| Number acquired | 1,106 |
| Number disposed | Nil |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation |
1,106 shares @ $4.56 via participation in the Dividend Reinvestment Plan |
| No. of securities held after change | 253,180 |
- See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Appendix 3Y Change of Director’s Interest Notice
Nature of change Issue of shares via participation in the Example: on-market trade, off-market trade, exercise of options, MVP Dividend Reinvestment Plan issue of securities under dividend reinvestment plan, participation in buy-back announced on 18 February 2016.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
==> picture [434 x 319] intentionally omitted <==
----- Start of picture text -----
Detail of contract Not applicable
Nature of interest
Name of registered holder
(if issued securities)
Date of change
No. and class of securities to which
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details
and an estimated valuation
Interest after change
----- End of picture text -----
Part 3 –[+] Closed period
Were the interests in the securities or contracts detailed No above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade N/A to proceed during this period? If prior written clearance was provided, on what date was this N/A provided?
- See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Appendix 3Y Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity Medical Developments International Limited ABN 14 106 340 667
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of Director | Leon Hoare |
|---|---|
| Date of last notice | 26 May 2015 |
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Direct or indirect interest | Direct |
|---|---|
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. |
Mr. Leon Hoare |
| Date of change | 8 April 2016 |
| No. of securities held prior to change | 10,000 |
| Class | Fully Paid Ordinary Shares |
| Number acquired | 43 |
| Number disposed | Nil |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation |
43 shares @ $4.56 via participation in the Dividend Reinvestment Plan |
| No. of securities held after change | 10,043 |
- See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Appendix 3Y Change of Director’s Interest Notice
Nature of change Issue of shares via participation in the Example: on-market trade, off-market trade, exercise of options, MVP Dividend Reinvestment Plan issue of securities under dividend reinvestment plan, participation in buy-back announced on 18 February 2016.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
==> picture [434 x 319] intentionally omitted <==
----- Start of picture text -----
Detail of contract Not applicable
Nature of interest
Name of registered holder
(if issued securities)
Date of change
No. and class of securities to which
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details
and an estimated valuation
Interest after change
----- End of picture text -----
Part 3 –[+] Closed period
Were the interests in the securities or contracts detailed No above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade N/A to proceed during this period? If prior written clearance was provided, on what date was this N/A provided?
- See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011